News | January 31, 2008

Corgenix AspirinWorks Test Now Offered Through Quest Diagnostics

January 31, 2008 - Corgenix Medical Corp. has announced that its AspirinWorks test is available to physicians and other laboratories through Quest Diagnostics Inc., a provider of diagnostic testing, information and services.

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin’s target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient’s therapy.

Unlike other tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor’s office, making the test easy for both physician and patient.

The AspirinWorks test, which was launched in 2007 following FDA 510(k) clearance, is now available nationwide through a growing list of national and regional clinical laboratories. Simpson said additional supporting clinical data and scientific articles scheduled for publication in 2008 will further enhance the science and clinical validation behind aspirin effect testing.

The AspirinWorks test is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.

For more information: www.aspirinworks.com

Overlay Init